328233-02-9

Basic information

• Product Name: tert-butyl 2-benzyl-3-oxo-2,2',3,3'-tetrahydro-1'H-spiro[isoindole-1,4'-pyridine]-1'-carboxylate
• Synonyms: tert-butyl 2-benzyl-3-oxo-2,2',3,3'-tetrahydro-1'H-spiro[isoindole-1,4'-pyridine]-1'-carboxylate
• CAS NO: 328233-02-9
• Molecular Weight: 390.482
• Mol File: 328233-02-9.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-benzyl-3-oxo-2,2',3,3'-tetrahydro-1'H-spiro[isoindole-1,4'-pyridine]-1'-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-benzyl-3-oxo-2,2',3,3'-tetrahydro-1'H-spiro[isoindole-1,4'-pyridine]-1'-carboxylate(328233-02-9)
• EPA Substance Registry System: tert-butyl 2-benzyl-3-oxo-2,2',3,3'-tetrahydro-1'H-spiro[isoindole-1,4'-pyridine]-1'-carboxylate(328233-02-9)

Safety Data

• Hazardous Substances Data: 328233-02-9(Hazardous Substances Data)

Upstream product

• 328233-01-8 N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide 

Downstream Products

• 920023-54-7 1'-tert-butyloxycarbonylspiro[isoindoline-1,4'-piperidine]-3-one 
• 889139-51-9 2-benzyl-2',3'-dihydro-1'H-spiro[isoindole-1,4'-pyridin]-3(2H)-one 
• 328233-03-0 2-benzyl-1'-tert-butoxycarbonylspiro[1H-isoindole-1,4'-piperidine]-3(2H)-one 

Relevant articles and documents

DIPIPERAZINYL KETONES AND RELATED ANALOGUES

Dipiperazinyl ketones and related analogues are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF

The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1, R2, Q1-Q3, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

Spiro compounds

Compounds of the general formula (I): wherein Ar1represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.

Novel spiro compounds

Compounds of the general formula (I): wherein Ar1 represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.

Spiro compounds

Spiro compounds of the general formula (I): wherein Ar1represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents methine; Y represents an optionally substituted imino or oxygen atom. These novel spiro compounds exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.

Spiro compounds

Spiro compounds of the general formula (I): wherein Ar1represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents nitrogen; Y represents an optionally substituted imino or oxygen atom, which exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.